Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.72 |
| ▸ | ECE1 | P42892 | 11/20 | 0.61 |
| ▸ | MMP1 | P03956 | 1/20 | 0.61 |
| ▸ | MMP3 | P08254 | 1/20 | 0.61 |
| ▸ | MMP9 | P14780 | 1/20 | 0.61 |
| ▸ | MMP8 | P22894 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | APAF1 | O14727 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | RECQL | P46063 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26817747 | 0.89 | ACE (0.69) | ACEECE1MMP1MMP3MMP9 | |
| SCHEMBL16301507 | 0.88 | ECE1 (0.66) | ACEECE1MMP1MMP3MMP9 | |
| SCHEMBL26169713 | 0.88 | ECE1 (0.66) | ACEECE1MMP1MMP3MMP9 | |
| SCHEMBL21929715 | 0.87 | ACE (0.61) | ACEECE1MMP1MMP3MMP9 | |
| SCHEMBL7854107 | 0.84 | KDM4E (0.70) | ACEECE1MMP1MMP3MMP9 | |
| SCHEMBL6165601 | 0.84 | ACE (1.00) | ACEECE1 | |
| SCHEMBL11483619 | 0.84 | ACE (1.00) | ACEECE1 | |
| SCHEMBL26168931 | 0.83 | POLB (0.62) | ACEECE1MMP1MMP3MMP9 | |
| SCHEMBL13723039 | 0.83 | MMP9 (0.57) | ACEECE1MMP1MMP3MMP9 | |
| SCHEMBL24915375 | 0.83 | ACE (0.67) | ACEECE1MMP1MMP3MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10919937-B2 | Bicyclic peptide ligands and uses thereof | BICYCLETX LIMITED (GB) | 2021-02-16 | — | — | US | disclosed |
| US-20200131228-A1 | BICYCLIC PEPTIDE LIGANDS AND USES THEREOF | BICYCLETX LIMITED (GB) | 2020-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131228-A1 | BICYCLIC PEPTIDE LIGANDS AND USES THEREOF | VIP, NGLY1, BID | ACE 1059/4885ECE1 657/4885MMP1 3376/4885 |
| US-10919937-B2 | Bicyclic peptide ligands and uses thereof | VIP, NGLY1, BID | ACE 1059/4885ECE1 657/4885MMP1 3376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.